CN105412136A - Composition for treating cardiovascular and cerebrovascular diseases, drug prepared from composition, and application - Google Patents
Composition for treating cardiovascular and cerebrovascular diseases, drug prepared from composition, and application Download PDFInfo
- Publication number
- CN105412136A CN105412136A CN201510937664.5A CN201510937664A CN105412136A CN 105412136 A CN105412136 A CN 105412136A CN 201510937664 A CN201510937664 A CN 201510937664A CN 105412136 A CN105412136 A CN 105412136A
- Authority
- CN
- China
- Prior art keywords
- dicaffeoyl
- quinic acid
- composition
- compositions
- cerebrovascular diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a composition for treating cardiovascular and cerebrovascular diseases, a drug prepared from the composition, and application. The composition comprises the following components in percentage by weight: 1-60% of isochlorogenic acid A, 30% of scutellarin, and 10-69% of a mixture of isochlorogenic acid C, 1,5-dicaffeoylquinic acid and erigoster. The drug comprises the composition and a pharmaceutically acceptable drug carrier or an excipient, and is used for treating the cardiovascular and cerebrovascular diseases. Compared with the prior art, the composition and the drug provided by the invention has the advantages that the effect onset time for inhibiting thrombosis and platelet aggregation is obviously shortened, the inhibition ratio is obviously improved, the drug effect can be exerted more quickly during clinical application, and then a patient can be cured more timely.
Description
Technical field
The present invention relates to and be a kind ofly used for the treatment of the compositions of ischemic cardio cerebrovascular diseases and the medicine of preparation thereof and application, belong to medicinal application field.
Background technology
In recent years, the sickness rate of the cardiovascular and cerebrovascular disease of China constantly rises, and age of onset also shifts to an earlier date to some extent, and the control of cardiovascular and cerebrovascular disease has become important public health problem.
Ischemic cardio cerebrovascular diseases refers to the heart, brain blood supply obstacle that a variety of causes causes, and make the heart, brain tissue ischemia, Hypoxic downright bad, cause a class disease of local heart and brain tissues generation irreversibility infringement, acute attack is very harmful to body.As do not treated in time, the sequela such as hemiplegia, physical handicaps, facial hemiparalysis may be left, have a strong impact on patients ' life quality.
Ischemic cardio cerebrovascular diseases due to therapeutic time window narrow, timely diagnosis and treatment are most important, during Clinical Processing, stress early diagnosis, early treatment in particular.After morbidity, have 1,900,000 nerve cell deaths because anoxia is per minute, but within a certain period of time, the surrounding tissue institute damaged of necrotic lesion is still reversible, if treatment can be accepted immediately, will significantly reduces disabled risk.Therefore, except should just controlling as early as possible after morbidity, the onset time speed being used for the treatment of the medicine of this type of disease is also the key factor affecting therapeutic effect.The drug effect time is shorter, and therapeutic effect is better, and the irreversible degree of injury that disease causes is lighter, sequela less or degree lighter.
In ischemic cardio cerebrovascular diseases clinical treatment, inhibition thrombosis and antiplatelet aggregation are the most frequently used remedy measures.
Patent documentation CN1173707C discloses a kind of pharmaceutical composition be made up of the scutellarin of 5 ~ 25% and the caffeoylquinic acids of 45 ~ 95% or its officinal salt; Patent documentation CN100374120C discloses a kind of Herba Erigerontis effective site erigeron breviscapus; primarily of active component scutellarin, 3; 5-dicaffeoyl-quinic acid, 1; 5-dicaffeoyl-quinic acid, Erigeroster B and 4; 5-dicaffeoyl-quinic acid forms; wherein scutellarin content 10-40%, four caffeic acid ester content sums are at 40-60%.Both all can be used for treating cardiovascular and cerebrovascular disease, and the pharmaceutical composition also all openly provided in two parts of documents or effective site can suppress thrombosis generation, anticoagulant.
Compositions provided by the invention; be made up of three parts, respectively: (1) 3,5-dicaffeoyl-quinic acid, (2) scutellarin and (3) 4; 5-dicaffeoyl-quinic acid+1,5-dicaffeoyl-quinic acid+Erigeroster B mixture.By 3; 5-dicaffeoyl-quinic acid, scutellarin and 4; 5-dicaffeoyl-quinic acid+1; 5-dicaffeoyl-quinic acid+Erigeroster B mixture combines in specific proportions; compared with prior art, the onset time of its inhibition thrombosis and anticoagulant obviously shortens, and suppression ratio significantly improves; can fast onset drug effect more in clinical practice, make patient obtain giving treatment to more timely.
Summary of the invention
The object of this invention is to provide a kind of compositions being used for the treatment of ischemic cardio cerebrovascular diseases.
Another object of the present invention is to provide a kind of medicine being used for the treatment of ischemic cardio cerebrovascular diseases prepared by described compositions.
The medicine that present invention also offers described compositions and preparation thereof is used for the treatment of the application of ischemic cardio cerebrovascular diseases.
Technical scheme of the present invention is as follows:
On the one hand; the invention provides a kind of compositions being used for the treatment of ischemic cardio cerebrovascular diseases; described compositions is 3 of 1-60% by percentage by weight; 5-dicaffeoyl-quinic acid and the scutellarin of 30% and 4 of 10-69%; 5-dicaffeoyl-quinic acid+1; 5-dicaffeoyl-quinic acid+Erigeroster B mixture composition, total amount is 100%.
Preferably; described compositions is 4, the 5-dicaffeoyl-quinic acid+1 of 3, the 5-dicaffeoyl-quinic acid of 10-50% and the scutellarin of 30% and 20-60% by percentage by weight; 5-dicaffeoyl-quinic acid+Erigeroster B mixture composition, total amount is 100%.
More preferably; described compositions is 4, the 5-dicaffeoyl-quinic acid+1 of 3, the 5-dicaffeoyl-quinic acid of 20-40% and the scutellarin of 30% and 30-50% by percentage by weight; 5-dicaffeoyl-quinic acid+Erigeroster B mixture composition, total amount is 100%.
On the other hand, the invention provides a kind of medicine being used for the treatment of ischemic cardio cerebrovascular diseases, described medicine contains the compositions of the invention described above and pharmaceutically acceptable pharmaceutical carrier or excipient.
Preferably, described medicine is oral formulations or injection.
Compositions and the medicine being used for the treatment of ischemic cardio cerebrovascular diseases provided by the invention; by 3; 5-dicaffeoyl-quinic acid, scutellarin and 4; 5-dicaffeoyl-quinic acid+1; 5-dicaffeoyl-quinic acid+Erigeroster B mixture combines in specific proportions, and compared with prior art, the onset time of its inhibition thrombosis and anticoagulant obviously shortens; suppression ratio significantly improves, and creates beyond thought effect.
Specific embodiments
embodiment 1
3, the 5-dicaffeoyl-quinic acid of 1% and the scutellarin of 30% and 69% 4,5-dicaffeoyl-quinic acid+1,5-dicaffeoyl-quinic acid+Erigeroster B mixture, mix homogeneously, to obtain final product.
embodiment 2
3, the 5-dicaffeoyl-quinic acid of 10% and the scutellarin of 30% and 60% 4,5-dicaffeoyl-quinic acid+1,5-dicaffeoyl-quinic acid+Erigeroster B mixture, mix homogeneously, to obtain final product.
embodiment 3
3, the 5-dicaffeoyl-quinic acid of 20% and the scutellarin of 30% and 50% 4,5-dicaffeoyl-quinic acid+1,5-dicaffeoyl-quinic acid+Erigeroster B mixture, mix homogeneously, to obtain final product.
embodiment 4
3, the 5-dicaffeoyl-quinic acid of 30% and the scutellarin of 30% and 40% 4,5-dicaffeoyl-quinic acid+1,5-dicaffeoyl-quinic acid+Erigeroster B mixture, mix homogeneously, to obtain final product.
embodiment 5
3, the 5-dicaffeoyl-quinic acid of 40% and the scutellarin of 30% and 30% 4,5-dicaffeoyl-quinic acid+1,5-dicaffeoyl-quinic acid+Erigeroster B mixture, mix homogeneously, to obtain final product.
embodiment 6
3, the 5-dicaffeoyl-quinic acid of 50% and the scutellarin of 30% and 20% 4,5-dicaffeoyl-quinic acid+1,5-dicaffeoyl-quinic acid+Erigeroster B mixture, mix homogeneously, to obtain final product.
embodiment 7
3, the 5-dicaffeoyl-quinic acid of 60% and the scutellarin of 30% and 10% 4,5-dicaffeoyl-quinic acid+1,5-dicaffeoyl-quinic acid+Erigeroster B mixture, mix homogeneously, to obtain final product.
embodiment 8
Arbitrary composition in Example 1-7, adds pharmaceutical carrier and the excipient such as lactose, starch, magnesium stearate, makes the drug oral preparation that tablet, capsule, granule etc. are used for the treatment of ischemic cardio cerebrovascular diseases.
embodiment 9
Arbitrary composition in Example 1-7, adds pharmaceutical carrier and the excipient such as mannitol, sodium bicarbonate, hydrochloric acid, sodium chloride, makes the drug injection liquid formulation being used for the treatment of ischemic cardio cerebrovascular diseases.
embodiment 10
Arbitrary composition in Example 1-7, adds the pharmaceutic adjuvants such as mannitol, sodium bicarbonate, hydrochloric acid, sodium chloride, is mixed with solution, after aseptic filtration, through lyophilization, makes the drug injection injectable powder being used for the treatment of ischemic cardio cerebrovascular diseases.
concrete test example
1, test material
(1) experimental animal
SD rat, Shanghai western pul-Bi Kai laboratory animal company limited provides, No. 152, Shanghai dynamic circuit connector lattice word.
(2) test specimen
Totally 3, the sample be for experiment, numbers with A, B, C.
A: the compositions (in embodiment 1-10, any one compositions or medicine can reach same effect) that embodiment 4 provides.
B: the compositions (wherein the content of scutellarin is 5%, and the content of caffeoylquinic acids is 95%, and total amount is 100%) preparing gained according to CN1173707C patent documentation contents;
C: the compositions (wherein scutellarin content is 40%, and total coffee acid ester content is 60%, and total amount is 100%) preparing gained according to CN100374120C patent documentation contents;
2, test method
(1) rat arteriovenous shunt thrombosis generates test
Healthy male SD rat 200, be divided into solvent control group, sample A, sample B, sample C totally four groups at random, often organize 50, each administration group dosage is 30mg/kg, solvent control group gives to wait the blank solvent of dosage, single intravenous injection administration, respectively at after 0min, administration 3,6,9,12min totally 5 different time points observe rat arteriovenous shunt thrombosis formed after wet weight of thrombus, often organize each time point 10 rats.Rat arteriovenous shunt thrombosis forms test method: SD rats by intraperitoneal injection is anaesthetized, and dorsal position fixes circulation of qi promoting cannula, and is separated right common carotid artery and left external jugular vein.Left external jugular vein is inserted in built-in long 6cm silk thread, polyethylene tube one end of being full of heparin-saline solution, and the other end inserts right common carotid artery.At corresponding time point place after intravenous administration, open bulldog clamp, make blood in polyethylene tube, return left external jugular vein from right common carotid artery.Open blood flow is middle Herba Clinopodii after 15 minutes, and take out rapidly silk thread and weigh, gross weight deducts silk thread weight, obtains thrombosis growing amount.Suppression ratio=(sample group ﹣ solvent control group)/solvent control group
Result of the test is in table 1.
Table 1 rat arteriovenous shunt thrombosis generation test (
n=10)
* P < 0.05vs solvent control group; * P < 0.01vs solvent control group
Experimentally result is known, compositions provided by the present invention (sample A) upon administration 3min can obviously suppress thrombosis to generate, suppression ratio reaches 23.58%, the compositions (sample B) that patent documentation CN1173707C provides and the compositions (sample C) that patent documentation CN100374120C provides, just produce the effect suppressing thrombosis to generate when being all 9min after administration, suppression ratio is respectively 21.55%, 20.26%.Point at one time, sample B and sample C to the suppression ratio of thrombosis all lower than compositions provided by the present invention (sample A).
(2) rat platelet aggregation function test
Healthy male SD rat 200, be divided into solvent control group, sample A, sample B, sample C totally four groups at random, often organize 50, each administration group dosage is 30mg/kg, solvent control group gives to wait the blank solvent of dosage, single intravenous injection administration, respectively at after 0min, administration 1,3,5,7min totally 5 different time points pentobarbital sodium intraperitoneal injection of anesthesia rats, ventral aorta is taken a blood sample, anticoagulant heparin, prepares platelet rich plasma (PRP) and platelet poor plasma (PPP).By turbidimetry for Determination platelet aggregation degree, add to PPP with the buffer of equivalent or medicinal liquid and oppose and look after zeroising, medicinal liquid is added in PRP, 37 DEG C of incubations, then with ADP4 μm of ol/L induced platelet aggregation.Trace optical density curve, using curve rising peak as maximum agglutination rate, ask each group of average aggregate rate, reduce amplitude with curve and calculate medicine to hematoblastic inhibitory action.
Platelet aggregation inhibition rate=(solvent control group average aggregate rate ﹣ investigational agent average aggregate rate)/solvent control group average aggregate rate.
Result of the test is in table 2.
Table 2 on the impact of ADP induced rat platelet aggregation (
n=10)
* P < 0.05vs solvent control group; * P < 0.01vs solvent control group
Experimentally result is known, compositions provided by the present invention (sample A) upon administration 1min gets final product obvious anticoagulant, assemble suppression ratio and reach 19.4%, the effect suppressing anticoagulant is just produced when the compositions that patent documentation CN1173707C (sample B) provides is 7min after administration, just produce the effect of anticoagulant when the compositions that patent documentation CN100374120C (sample C) provides is 5min after administration, suppression ratio is respectively 20.4%, 18.6%.Point at one time, sample B and sample C is all starkly lower than compositions provided by the present invention (sample A) to the suppression ratio of platelet aggregation.
3, conclusion (of pressure testing)
(1) rat arteriovenous shunt thrombosis generation result of the test shows, compositions provided by the invention and medicine have the effect obviously suppressing thrombosis to generate, and compared with prior art, onset time obviously shortens, and suppression ratio significantly improves.
(2) result of the test that affects of ADP induced rat platelet aggregation is shown, compositions provided by the invention and medicine have the effect of the platelet aggregation obviously suppressing ADP induction, compared with prior art, onset time obviously shortens, and suppression ratio significantly improves.
Claims (7)
1. one kind is used for the treatment of the compositions of ischemic cardio cerebrovascular diseases; described compositions is 3 of 1-60% by percentage by weight; 5-dicaffeoyl-quinic acid and the scutellarin of 30% and 4 of 10-69%; 5-dicaffeoyl-quinic acid+1; 5-dicaffeoyl-quinic acid+Erigeroster B mixture composition, total amount is 100%.
2. compositions according to claim 1; it is characterized in that; described compositions is 3 of 10-50% by percentage by weight; 5-dicaffeoyl-quinic acid and the scutellarin of 30% and 4 of 20-60%; 5-dicaffeoyl-quinic acid+1; 5-dicaffeoyl-quinic acid+Erigeroster B mixture composition, total amount is 100%.
3. compositions according to claim 2; it is characterized in that; described compositions is 3 of 20-40% by percentage by weight; 5-dicaffeoyl-quinic acid and the scutellarin of 30% and 4 of 30-50%; 5-dicaffeoyl-quinic acid+1; 5-dicaffeoyl-quinic acid+Erigeroster B mixture composition, total amount is 100%.
4. medicine prepared by the compositions according to claims 1 to 3 any one, is characterized in that, described medicine contains compositions described in claims 1 to 3 any one and pharmaceutically acceptable pharmaceutical carrier or excipient.
5. medicine according to claim 4, is characterized in that, described medicine is oral formulations.
6. medicine according to claim 4, is characterized in that, described medicine is injection.
7. the compositions in claim 1 to 6 described in any one or medicine are used for the treatment of ischemic cardio cerebrovascular diseases.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510937664.5A CN105412136B (en) | 2015-12-16 | 2015-12-16 | It is a kind of to be used to treat the composition of ischemic angiocardiopathy and cerebrovascular disease and its medicine of preparation and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510937664.5A CN105412136B (en) | 2015-12-16 | 2015-12-16 | It is a kind of to be used to treat the composition of ischemic angiocardiopathy and cerebrovascular disease and its medicine of preparation and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105412136A true CN105412136A (en) | 2016-03-23 |
| CN105412136B CN105412136B (en) | 2018-05-04 |
Family
ID=55490987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510937664.5A Active CN105412136B (en) | 2015-12-16 | 2015-12-16 | It is a kind of to be used to treat the composition of ischemic angiocardiopathy and cerebrovascular disease and its medicine of preparation and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105412136B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022143513A1 (en) * | 2020-12-29 | 2022-07-07 | 云南生物谷药业股份有限公司 | Oral preparation comprising erigeron breviscapus extract and preparation method therefor |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1462620A (en) * | 2003-04-22 | 2003-12-24 | 中国科学院昆明植物研究所 | Powder of flenabane and its preparation method as well as application in making drugs |
-
2015
- 2015-12-16 CN CN201510937664.5A patent/CN105412136B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1462620A (en) * | 2003-04-22 | 2003-12-24 | 中国科学院昆明植物研究所 | Powder of flenabane and its preparation method as well as application in making drugs |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022143513A1 (en) * | 2020-12-29 | 2022-07-07 | 云南生物谷药业股份有限公司 | Oral preparation comprising erigeron breviscapus extract and preparation method therefor |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105412136B (en) | 2018-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5775246B2 (en) | Method of using resiniferatoxin (RTX) for producing a medicament for treating joint pain and method of applying said medicament | |
| CN1895332A (en) | Oral and externally-applied Chinese medicinal preparation for treating osteoproliferation and its production | |
| CN105998019A (en) | Medicine composition for treating brain glioma and application thereof | |
| CN104628657A (en) | Class of compounds for treating ischemic brain damage and purpose thereof | |
| CN105412136A (en) | Composition for treating cardiovascular and cerebrovascular diseases, drug prepared from composition, and application | |
| CN105663385A (en) | Meng-medicinal analgesic paste and preparation method thereof | |
| CN107072994A (en) | Levosimendan for treating motor neuron disease (such as ALS) | |
| CN109528924B (en) | Traditional Chinese medicine composition for preventing and treating deep vein thrombosis after joint replacement surgery | |
| CN102961517B (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular disease | |
| CN105982887A (en) | Application of arctigenin in preparing medicine for treating blood hyperviscosity | |
| CN104324250A (en) | Traditional Chinese medicine composition for cerebral arterial thrombosis and preparation method of traditional Chinese medicine composition | |
| EA200900214A1 (en) | PHARMACEUTICAL COMPOSITION OF RIFABUTIN FOR THE TREATMENT OF TUBERCULOSIS, THE WAY OF ITS OBTAINING AND THE METHOD OF TREATMENT | |
| CN101467967A (en) | Double-element solution type preparation for intravenous injection and intracerebral injection | |
| CN106728119A (en) | Application of the cerebral ischemic Chinese medicine composition in treatment cerebral hemorrhage medicine is prepared | |
| CN102764280A (en) | Bezoar and musk containing pharmaceutical composition and its application | |
| JP2006219380A (en) | Glycyrrhizin subcutaneous injection preparation | |
| CN105963287B (en) | Compound and its medical usage | |
| CN103356951B (en) | A kind of Chinese medicine composition for the treatment of cardiac blood supply deficiency | |
| CN106421422A (en) | Traditional Chinese medicine composition for curing insomnia | |
| CN105560427A (en) | Transdermal gate-freeing powder | |
| CN104352671A (en) | Novel medical application of traditional Chinese medicine composition | |
| RU2020111649A (en) | Treatment of pathological bone conditions in patients with acid sphingomyelinase deficiency | |
| JP2024502662A (en) | Application of compositions containing cilostazol to the preparation of therapeutic agents for cerebrovascular diseases | |
| CN105343454A (en) | Traditional Chinese medicinal capsule for treating thrombus, and preparation method thereof | |
| CN104435664A (en) | Red-bean-containing pharmaceutical composition for treating cardiovascular and cerebrovascular diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |